Drug maker Lupin said Monday it has received an approval from the US health regulator to market its Triamcinolone Acetonide ointment, used to treat skin conditions, in the US market.
The company has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Mylan Pharmaceuticals Inc's Triamcinolone Acetonide Ointment, Lupin said in a statement.
As per the IQVIA MAT June 2018 sales data, Triamcinolone Acetonide Ointment had annual sales of around USD 25.7 million in the US.
Lupin shares Monday ended 0.51 per cent up at Rs 882.10 on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
